ARID1A and ovarian carcinoma: We, therefore, tested the sensitivity of additional ARID1A-mutant or endometriosis-related ovarian cancer cell lines to tolinapant and entinostat to evaluate whether these characteristics might serve as markers for sensitivity to SMAC mimetics.